February 14, 2017 / 12:18 PM / in 5 months

BRIEF-Incyte reports Q4 earnings per share $0.05

1 Min Read

Feb 14 (Reuters) - Incyte Corp

* Incyte reports 2016 fourth-quarter and year-end financial results, provides 2017 financial guidance and updates on key clinical programs

* Q4 revenue $326 million versus I/B/E/S view $324.4 million

* Q4 earnings per share $0.05

* Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S

* Sees 2017 Jakafi net product revenues $1,020-$1,070 million

* Sees 2017 ongoing research and development expenses $785-$835 million

* Sees 2017 change in fair value of acquisition-related contingent consideration $30-$35 million

* Incyte Corp - pivotal program of ruxolitinib as a treatment for patients with essential thrombocythemia is also expected to begin in 2017

* Incyte - phase 3 trials in steroid-refractory acute, steroid-refractory chronic gvhd, respectively, expected to begin in 2017 with novartis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below